科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02171 科济药业-B

已收盘 12-19 16:08:47

8.690

-0.190

-2.14%

最高9.490	最低8.570	成交量786.95万
今开9.040	昨收8.880	日振幅10.36%
总市值49.67亿	流通市值49.67亿	总股本5.72亿
成交额6,992万	换手率1.38%	流通股本5.72亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02171","market":"HK","secType":"STK","nameCN":"科济药业-B","latestPrice":8.69,"timestamp":1734595727014,"preClose":8.88,"halted":0,"volume":7869500,"delay":0,"floatShares":571539915,"shares":571539915,"eps":-1.4424336,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.19,"latestTime":"12-19 16:08:47","open":9.04,"high":9.49,"low":8.57,"amount":69918182,"amplitude":0.103604,"askPrice":8.69,"askSize":13000,"bidPrice":8.68,"bidSize":50000,"shortable":3,"etf":0,"ttmEps":-1.3384955687469866,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1734658200000},"adr":0,"listingDate":1623945600000,"adjPreClose":8.88,"openAndCloseTimeList":[[1734571800000,1734580800000],[1734584400000,1734595200000]],"volumeRatio":0.728841,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02171/tweets","defaultTab":"tweets","newsList":[{"id":"1151431026","title":"异动解读 | 科济药业-B盘中大涨6.31% 潜在原因或与创新CAR-T细胞疗法有关","url":"https://stock-news.laohu8.com/highlight/detail?id=1151431026","media":"异动解读","labels":["movement"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151431026?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:57","pubTimestamp":1734573448,"startTime":"0","endTime":"0","summary":"2024年12月19日上午9时30分,科济药业-B(02171)股价在港股盘中突然出现大涨超过6%的异动。据悉,造成这一走势的原因很可能与该公司在研发创新CAR-T细胞疗法方面取得进展有关。\n\n作为一家专注于创新免疫细胞疗法的公司,科济药业-B的核心产品是升级版靶向B细胞成熟抗原(BCMA)的CAR-T疗法CT053,用于治疗血液肿瘤及实体瘤。公司可能在相关临床试验或监管审批等环节获得利好消息,提振了市场对公司长期发展前景的信心。\n\n不过,由于尚无确切的消息来源可供佐证,上述推测仍需进一步的官方披露或报道予以证实。科济药业-B此次大涨究竟是基于什么实质性进展,市场拭目以待公司的进一步说明。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 科济药业-B盘中大涨6.31% 潜在原因或与创新CAR-T细胞疗法有关","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"gpt_icon":0},{"id":"2492938961","title":"科济药业-B盘中异动 快速拉升5.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492938961","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492938961?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:30","pubTimestamp":1734571853,"startTime":"0","endTime":"0","summary":"2024年12月19日早盘09时30分，科济药业-B股票出现异动，股价快速上涨5.63%。截至发稿，该股报9.380港元/股，成交量34.35万股，换手率0.06%，振幅5.29%。科济药业-B股票所在的生物技术行业中，整体跌幅为0.58%。其相关个股中，科济药业-B、云康集团、腾盛博药-B涨幅较大，振幅较大的相关个股有科济药业-B、歌礼制药-B、晶泰控股-P，振幅分别为5.29%、5.28%、5.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093102984cbfa0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093102984cbfa0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1587","BK1585","BK1574","02171"],"gpt_icon":0},{"id":"2492863198","title":"南向资金12月18日净买入科济药业-B155.60万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2492863198","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492863198?lang=zh_cn&edition=full","pubTime":"2024-12-19 09:30","pubTimestamp":1734571820,"startTime":"0","endTime":"0","summary":"12月18日, 南向资金增持科济药业-B155.60万股，连续3日增持。截止当日收盘，港股通共持有科济药业-B15342.02万股，占流通股26.83%。港股通增持金额前五个股分别为中国移动、工商银行、建设银行、中国海洋石油、中国平安。科济药业-B近5个交易日下跌16.70%，港股通累计减持232.50万股；近20个交易日上涨20.49%，港股通累计增持320.90万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093456a1f9e0f7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241219093456a1f9e0f7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1585","BK1161","BK1587","02171","BK1574"],"gpt_icon":0},{"id":"2492923615","title":"科济药业-B(02171)下跌5.0%，报8.74元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492923615","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492923615?lang=zh_cn&edition=full","pubTime":"2024-12-18 11:42","pubTimestamp":1734493366,"startTime":"0","endTime":"0","summary":"12月18日，科济药业-B(02171)盘中下跌5.0%，截至11:42，报8.74元/股，成交3707.34万元。科济药业控股有限公司是一家专注于开发创新嵌合抗原受体T细胞（CAR-T）疗法，治疗实体瘤和血液恶性肿瘤的生物制药公司。其主要产品包括用于治疗复发/难治多发性骨髓瘤的自体BCMA CAR-T细胞产品泽沃基奥仑赛注射液，以及全球首个进入确证性临床试验的靶向Claudin18.2的自体CAR-T细胞候选产品，用于治疗胃癌、胰腺癌及其他实体瘤的舒瑞基奥仑赛注射液。截至2024年中报，科济药业-B营业总收入634.0万元、净利润-3.52亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/18114246524784.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1585","BK1574","BK1587","BK1161","02171"],"gpt_icon":0},{"id":"2492674002","title":"科济药业-B(02171)下跌5.08%，报9.16元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2492674002","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492674002?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:48","pubTimestamp":1734400082,"startTime":"0","endTime":"0","summary":"12月17日，科济药业-B(02171)盘中下跌5.08%，截至09:48，报9.16元/股，成交952.15万元。科济药业控股有限公司是一家专注于开发创新嵌合抗原受体T细胞（CAR-T）疗法，治疗实体瘤和血液恶性肿瘤的生物制药公司。其主要产品包括用于治疗复发/难治多发性骨髓瘤的自体BCMA CAR-T细胞产品泽沃基奥仑赛注射液，以及全球首个进入确证性临床试验的靶向Claudin18.2的自体CAR-T细胞候选产品，用于治疗胃癌、胰腺癌及其他实体瘤的舒瑞基奥仑赛注射液。截至2024年中报，科济药业-B营业总收入634.0万元、净利润-3.52亿元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/17094846455843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1585","BK1587","02171","BK1161","BK1574"],"gpt_icon":0},{"id":"2492677054","title":"科济药业-B盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2492677054","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2492677054?lang=zh_cn&edition=full","pubTime":"2024-12-17 09:47","pubTimestamp":1734400076,"startTime":"0","endTime":"0","summary":"2024年12月17日早盘09时47分，科济药业-B股票出现波动，股价大幅下跌5.08%。截至发稿，该股报9.160港元/股，成交量102.25万股，换手率0.18%，振幅8.08%。科济药业-B股票所在的生物技术行业中，整体涨幅为0.17%。科济药业-B公司简介：科济药业控股有限公司是一家主要从事创新嵌合抗原受体T 细胞疗法发现、开发及销售业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217094756ab7dc8e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217094756ab7dc8e0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02171","BK1587","BK1574","BK1161","BK1585"],"gpt_icon":0},{"id":"2491659950","title":"科济药业-B12月16日主力资金流出337万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2491659950","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2491659950?lang=zh_cn&edition=full","pubTime":"2024-12-16 16:16","pubTimestamp":1734336976,"startTime":"0","endTime":"0","summary":"12月16日, 科济药业-B股价跌0.31%，报收9.65元，成交金额7744万元，换手率1.42%，振幅8.16%，量比0.33。科济药业-B今日主力资金净流出337万元，连续3日净流出，上一交易日主力净流出286万元，今日环比增加17.83%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为50.00%，平均跌幅为3.80%。该股近5个交易日上涨32.19%，主力资金累计净流入6835万元；近20日主力资金累计净流入7912万元，其中净流入天数为10日。该股主力净额占比0.06%，港股市场排名2581/2651。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161655ab7bc974&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241216161655ab7bc974&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1585","BK1161","BK1574","02171"],"gpt_icon":0},{"id":"2490841337","title":"科济药业-B盘中异动 股价大跌5.44%报10.080港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490841337","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490841337?lang=zh_cn&edition=full","pubTime":"2024-12-12 09:30","pubTimestamp":1733967057,"startTime":"0","endTime":"0","summary":"2024年12月12日早盘09时30分，科济药业-B股票出现波动，股价大幅下跌5.44%。截至发稿，该股报10.080港元/股，成交量111.9万股，换手率0.20%，振幅4.41%。资金方面，该股资金流入404.916万港元，流出354.229万港元。科济药业-B股票所在的生物技术行业中，整体跌幅为0.37%。其相关个股中，晶泰控股-P、康宁杰瑞制药-B、迈博药业-B涨幅较大，振幅较大的相关个股有科济药业-B、歌礼制药-B、晶泰控股-P，振幅分别为4.32%、2.87%、2.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121209305795e9129d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121209305795e9129d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02171","BK1585","BK1574","BK1587","BK1161"],"gpt_icon":0},{"id":"2490173814","title":"金十数据全球财经早餐 | 2024年12月12日","url":"https://stock-news.laohu8.com/highlight/detail?id=2490173814","media":"金十数据","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490173814?lang=zh_cn&edition=full","pubTime":"2024-12-12 07:00","pubTimestamp":1733958000,"startTime":"0","endTime":"0","summary":"CPI数据完全符合预期，美联储12月降息几乎“板上钉钉”！黄金一度冲上2720美元；欧盟各国大使同意对俄罗斯实施第15轮制裁，两油大涨2%……昨日今晨，全球都发生了哪些大事？","market":"hk","thumbnail":"https://img.jin10.com/news/24/12/peAsuy2e4xgA5VFi1miwi.jpg/lite","type":0,"news_type":0,"thumbnails":["https://img.jin10.com/news/24/12/peAsuy2e4xgA5VFi1miwi.jpg/lite"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://xnews.jin10.com/webapp/details.html?id=155742&type=news&data_type=0","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"xnew_highlight","symbols":["06862","LU0965509283.SGD","NVDD","SNVD.UK","LU2237443382.USD","89618","LU1721428933.USD","LU0509642566.USD","NVDX","TME","3NVD.UK","LU0061474960.USD","01698","LU0106252389.USD","LU2764263039.SGD","NVD3.UK","LU0345776255.USD","NVDA","02171","LU2065170008.USD","NVDU","LU0823434740.USD","LU2092627202.USD","SCO","01992","NVD","LU0006306889.USD","LU1642822529.SGD","NVDY","USO","00780","09988","LU1868836757.USD","NVDS.UK","LU1804176565.USD","NVDS","BK4587","GOOG","NVD2.UK","LU2237443978.SGD","UCO","BABA","2NVD.UK","TSLA"],"gpt_icon":1},{"id":"2490838713","title":"港股收盘(12.10) | 恒指收跌0.77% 消费股、黄金股逆势走高 复星旅文(01992)放量暴涨80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2490838713","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490838713?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:39","pubTimestamp":1733906340,"startTime":"0","endTime":"0","summary":"截止收盘，恒生指数跌0.77%或156.23点，报20155.05点，全日成交额大幅缩减至1416.19亿港元；恒生国企指数跌0.78%，报7249.38点；恒生科技指数跌1.31%，报4531.58点。截至收盘，涨2.17%，报16.96港元，成交额4.31亿港元，贡献恒指1.1点。热门异动股1. 复星旅游文化放量暴涨。截至收盘，涨80.25%，报7.21港元。计划生效后，复星国际及复星控股将分别持有公司约98.44%及1.56%权益，公司股份于联交所的上市地位将被撤销。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223480.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1212","BK1198","09858","BK1587","YANG","MCHmain","01992","BK1100","HSI","BK1592","BK1544","HSCEI","02252","BK1164","02833","BK1585","513600","BK1161","BK1521","03330","159562","02171","HSTECH","BK1574","BK1555","BK1604","BK1237","HHImain","BK1240"],"gpt_icon":1},{"id":"2490880697","title":"科济药业-B上榜12月11日主力资金加仓幅度前10个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2490880697","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490880697?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:15","pubTimestamp":1733904916,"startTime":"0","endTime":"0","summary":"12月11日, 科济药业-B股价涨39.35%，报收10.66元，成交金额6.56亿元，换手率12.16%，振幅40.00%，量比7.97。科济药业-B今日主力资金净流入8891万元，上一交易日主力净流出165万元。该股近5个交易日上涨65.79%，主力资金累计净流入9279万元；近20日主力资金累计净流入1.00亿元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161526a1e59c8c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241211161526a1e59c8c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1587","02171","BK1574","BK1585"],"gpt_icon":1},{"id":"2490879568","title":"港股异动 | 科济药业-B(02171)涨幅扩大至40% 公司在ASH年会上展示多项成果 通用型CAR-T早期数据优异","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879568","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490879568?lang=zh_cn&edition=full","pubTime":"2024-12-11 16:02","pubTimestamp":1733904155,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B尾盘涨幅扩大至40%，截至发稿，涨39.35%，报10.66港元，成交额6.47亿港元。国投证券指出，根据公司2024年ASH年会披露的同种异体CAR-T药物CT0590的早期临床数据，CT0590已显示出可控的安全性，并在多名患者中实现了深度和持久的临床缓解，其未来更多样本量的数据值得静待。此外，目前已有多个研究表明出CAR-T药物在自身免疫疾病显示出临床治愈的潜力，未来公司CAR-T产品在自身免疫疾病领域的应用值得静待。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223446.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","BK1161","BK1587","ASH","02171","BK1574","BK4230","BK1585","CAR","BK4022","BK4109"],"gpt_icon":0},{"id":"2490004462","title":"“第九届智通财经资本市场年会暨上市公司颁奖典礼”26项大奖揭晓：245家公司分获殊荣!","url":"https://stock-news.laohu8.com/highlight/detail?id=2490004462","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490004462?lang=zh_cn&edition=full","pubTime":"2024-12-11 12:31","pubTimestamp":1733891515,"startTime":"0","endTime":"0","summary":"2024年12月11日上午，“第九届智通财经资本市场年会暨上市公司颁奖典礼” 在深圳隆重开幕。“第九届智通财经上市公司评选”自2016年启动以来，已连续成功举办9届。接近岁末，在全球资本的版图中，港股市场再度成为焦点。截至11月底，南向资金已连续17个月净流入，年内净买入总额突破7300亿港元，创下10年新高。剔除重复获奖，本届上市公司颁奖典礼共有245家公司及其高管分享这些荣誉。评选期间，吸引了超过1000家港美股上市公司积极参与。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223189.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01783","01598","02018","06122","01880","06633","01735","00826","02020","00291","01450","02100","01093","02171","00780","00799","00017","00855","01405","01117","00451","00268","01651","00798","01427","01471","02225","02137","02145","01378","00460","01121","09919","01083","02158","09896","06058","06677","01969","02105","06682","00003","01907","00552","01992","01519","02013","06680","06086"],"gpt_icon":0},{"id":"2490046990","title":"科济药业－Ｂ(02171)出现大手买入71.05万股，成交价$9.0，涉资639.45万","url":"https://stock-news.laohu8.com/highlight/detail?id=2490046990","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490046990?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:57","pubTimestamp":1733889420,"startTime":"0","endTime":"0","summary":"[大手成交]科济药业－Ｂ(02171)在上午11:57出现大手买入，成交量为71.05万，成交价为港币$9.0，涉资639.45万。至目前为止，股价升17.255%，今日最高价为$9.0，而最低价为$7.68，总成交量为2.055千万股，总成交金额港币$1.738亿。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145550051_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2412114095/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02171","BK1585","BK1587","BK1161","BK1574"],"gpt_icon":0},{"id":"2490001028","title":"科济药业－Ｂ(02171)股价大幅上升17.255%，现价港币$8.97","url":"https://stock-news.laohu8.com/highlight/detail?id=2490001028","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490001028?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:55","pubTimestamp":1733889300,"startTime":"0","endTime":"0","summary":"[上升股]科济药业－Ｂ(02171) 股价在上午11:55比前收市价大幅上升17.255%，现股价为港币$8.97。至目前为止，今日最高价为$8.97，而最低价为$7.68。总成交量为1.913千万股，总成交金额为港币$1.611亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133338093_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR241211560/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1587","BK1585","BK1161","BK1574","02171"],"gpt_icon":0},{"id":"2490600917","title":"港股异动 | 科济药业-B(02171)急升逾16% 公司在ASH年会展示赛恺泽、CT071和CT0590研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2490600917","media":"智通财经","labels":["dataReport","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490600917?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:43","pubTimestamp":1733888619,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科济药业-B急升逾16%，截至发稿，涨15.69%，报8.85港元，成交额1.26亿港元。消息面上，科济药业公布，CT0590、CT071和赛恺泽的更新结果已在第66届美国血液学会年会上进行报告。此外，公司此前公布，美国FDA已解除在美国的泽沃基奥仑赛注射液、舒瑞基奥仑赛注射液以及CT071的临床试验暂停。所述临床试验暂停与2023年12月FDA对公司位于北卡罗来纳州达勒姆的临床生产基地进行检查后发布的发现项有关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1223185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","LU2463526074.USD","ASH","BK1587","02171","BK1574","BK1585","BK4109"],"gpt_icon":0},{"id":"1172707945","title":"异动解读 | 科济药业-B股价盘中大涨5.23%,创新疗法有望带来巨大商业价值","url":"https://stock-news.laohu8.com/highlight/detail?id=1172707945","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172707945?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:16","pubTimestamp":1733887015,"startTime":"0","endTime":"0","summary":"消息面上,科济药业在中国及美国生物制药行业拥有多年研发经验,专注于创新CAR-T细胞疗法的研发。该公司的核心产品赛恺泽今年3月获国家药监局批准在中国地区新药上市,这是公司在中国大陆首款商业化产品。公司与华东医药就该产品在中国大陆地区的商业化权利签订协议,已获得订单5.25亿元人民币。行业分析人士认为,虽然CAR-T细胞疗法目前仍处于起步阶段,但其在治疗血液及实体肿瘤方面展现出巨大的潜力和商业价值。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 科济药业-B股价盘中大涨5.23%,创新疗法有望带来巨大商业价值","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02171"],"gpt_icon":0},{"id":"2490006310","title":"科济药业-B(02171)上涨5.1%，报8.04元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2490006310","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490006310?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:14","pubTimestamp":1733886880,"startTime":"0","endTime":"0","summary":"12月11日，科济药业-B(02171)盘中上涨5.1%，截至11:14，报8.04元/股，成交4362.51万元。科济药业控股有限公司是一家专注于开发创新嵌合抗原受体T细胞（CAR-T）疗法，治疗实体瘤和血液恶性肿瘤的生物制药公司。其主要产品包括用于治疗复发/难治多发性骨髓瘤的自体BCMA CAR-T细胞产品泽沃基奥仑赛注射液，以及全球首个进入确证性临床试验的靶向Claudin18.2的自体CAR-T细胞候选产品，用于治疗胃癌、胰腺癌及其他实体瘤的舒瑞基奥仑赛注射液。截至2024年中报，科济药业-B营业总收入634.0万元、净利润-3.52亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/12/11111446244534.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02171","BK1585","BK1574","BK1587","BK1161"],"gpt_icon":0},{"id":"2490006154","title":"科济药业-B盘中异动 早盘急速拉升5.10%报8.040港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2490006154","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490006154?lang=zh_cn&edition=full","pubTime":"2024-12-11 11:14","pubTimestamp":1733886879,"startTime":"0","endTime":"0","summary":"2024年12月11日早盘11时14分，科济药业-B股票出现波动，股价大幅上涨5.10%。截至发稿，该股报8.040港元/股，成交量551.8万股，换手率0.97%，振幅4.71%。资金方面，该股资金流入2891.02万港元，流出932.947万港元。科济药业-B股票所在的生物技术行业中，整体跌幅为0.47%。科济药业-B公司简介：科济药业控股有限公司是一家主要从事创新嵌合抗原受体T 细胞疗法发现、开发及销售业务的中国投资控股公司。该公司的疗法用于治疗血液恶性肿瘤和实体瘤。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121111144095e8d5e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024121111144095e8d5e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1585","BK1161","BK1574","02171"],"gpt_icon":0},{"id":"2490696260","title":"科济药业-B(02171)于2024年ASH年会上呈列的赛恺泽®、CT071 和CT0590的研究成果更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2490696260","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2490696260?lang=zh_cn&edition=full","pubTime":"2024-12-10 16:32","pubTimestamp":1733819537,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科济药业-B 公布，CT0590、CT071和赛恺泽 的更新结果已在第66届美国血液学会年会上进行报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1222709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2463526074.USD","BK4109","BK1585","BK1161","BK1587","02171","BK1574","ASH"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.carsgen.com","stockEarnings":[{"period":"1week","weight":-0.167},{"period":"1month","weight":0.4118},{"period":"3month","weight":1.8831},{"period":"6month","weight":0.6029},{"period":"1year","weight":0.4006},{"period":"ytd","weight":0.3662}],"compareEarnings":[{"period":"1week","weight":-0.0144},{"period":"1month","weight":0.0147},{"period":"3month","weight":0.1028},{"period":"6month","weight":0.1018},{"period":"1year","weight":0.2035},{"period":"ytd","weight":0.1653}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科济药业控股有限公司是一家主要从事创新嵌合抗原受体（CAR）T 细胞疗法发现、开发及销售业务的中国投资控股公司。该公司的疗法用于治疗血液恶性肿瘤和实体瘤。该公司已开发升级版靶向B细胞成熟抗原（BCMA）的CAR-T产品CT053。CT053为其的唯一核心候选产品。该公司在中国和美国开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.177045},{"month":2,"riseRate":0.666667,"avgChangeRate":0.218959},{"month":3,"riseRate":0,"avgChangeRate":-0.160429},{"month":4,"riseRate":0,"avgChangeRate":-0.124967},{"month":5,"riseRate":0.666667,"avgChangeRate":0.010432},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.000476},{"month":7,"riseRate":0.5,"avgChangeRate":-0.003478},{"month":8,"riseRate":0.5,"avgChangeRate":0.066002},{"month":9,"riseRate":0.5,"avgChangeRate":0.083194},{"month":10,"riseRate":0.75,"avgChangeRate":0.067361},{"month":11,"riseRate":0.5,"avgChangeRate":0.049974},{"month":12,"riseRate":0.5,"avgChangeRate":-0.048993}],"exchange":"SEHK","name":"科济药业-B","nameEN":"CARSGEN-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科济药业-B,02171,科济药业-B股票,科济药业-B股票老虎,科济药业-B股票老虎国际,科济药业-B行情,科济药业-B股票行情,科济药业-B股价,科济药业-B股市,科济药业-B股票价格,科济药业-B股票交易,科济药业-B股票购买,科济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科济药业-B(02171)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科济药业-B(02171)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}